Tagged with NORD

Thailand John Dawber, vice president and general manager of Novo Nordisk Thailand, offers his first impressions of the Thai market since moving from Japan. Dawber explains the current challenges and areas for improvement in diabetes treatment in Thailand, how the most innovative Novo Nordisk products have propelled the affiliate forward in…

Sweden Niels Abel Bonde, general manager of Novo Nordisk Sweden, explains the strategic significance of the Swedish market as an innovation-driven environment ideal to run pilot launches and real-world studies. He also breaks down the performance of the affiliate in its main therapeutic areas, as well as the positives and negatives…

Sweden Dr Göran A. Ando, former chairman of Novo Nordisk and a Swedish life sciences industry veteran, recently moved back to his home country after over 35 years abroad. He shares his view on Swedish healthcare today, which is striving to continue its strong tradition of collaboration. Although Sweden is struggling…

Spain Rafael Mella, general manager of Nordic Pharma Spain & Portugal, highlights the steps he has taken to set-up the foundations for the company in the Spanish market and how he has overcome the challenges of the fragmented healthcare system. Furthermore, he gives insight into the Nordic’s game-changing Rheumatoid Arthritis product,…

Korea Rana Azfar, vice-president & general manager of Novo Nordisk Korea offers his impressions of the Korean market since moving from Pakistan. Azfar discusses how the most innovative insulin products have propelled Novo Nordisk forward in Korea, and how Novo Nordisk is working with patients and doctors to address the misconceptions…

France Vincent Leonhardt explains how the French administration’s zeal for life science innovation can actually place pressure on some pharma SMEs. He also discusses the challenges he faced during his first 2.5 years at the helm of Nordic Pharma in France.   Over the last decade, Nordic Pharma has gained renown…

Algeria The Top 20 Pharma Companies in Algeria based on sales in 2017. Sanofi is way out in front with USD 458.6 million in sales, followed by local champion El Kendi with USD 254.1 million and Danish diabetes specialist Novo Nordisk with USD 239.1 million.

Portugal Olga Insua, the new American general manager for Novo Nordisk Portugal, fresh off the plane from Spain, provides an exclusive insight into her impressive career at the company, the blending of business practices from Europe and New Jersey, and why patients should always be at the center of every process.…

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

Brazil When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature sensitive biologicals, one understands the urgent need to develop solutions guaranteeing appropriate transport conditions in Brazil. “We may be vaguely…

UK Much of the new inward investment in the UK from international pharmaceutical companies is from those that wish their discovery science to be in close adjacency to the most successful basic science programmes in biomedicinein the world. The co-location of pharmaceutical discovery sciences adjacent to the best universities (AstraZeneca in Cambridge, Novo Nordisk…

India For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms of demographics, is the youngest nation in the world. The…